🧠 Hyperoxia in Acute Brain Injury: Friend or Foe?
Abstract: This commentary responds to Romero-García et al.’s meta-analysis linking arterial hyperoxemia (PaO₂ elevation) to worse neurological outcomes in acute brain injury (ABI). The authors argue that equating hyperoxemia with cellular hyperoxia and oxidative injury is an oversimplification. Physiological evidence shows that oxygen transport is constrained by hemoglobin binding and low blood solubility, meaning only dissolved O₂ diffuses to tissues. Hyperoxemia may not always translate to intracellular hyperoxia or reactive oxygen species (ROS) excess. Furthermore, hyperbaric oxygen therapy (HBO₂) shows potential neuroprotective benefits in certain ABI contexts, though evidence is limited.
Key Insights:
-
Hyperoxemia vs. hyperoxia: Elevated PaO₂ (blood) ≠ guaranteed intracellular O₂ overload. ROS generation depends on cellular metabolism and ischemia–reperfusion dynamics.
-
Brain vulnerability: High metabolic demand and polyunsaturated fatty acid content make the brain sensitive to oxidative stress, but ROS findings in ABI are inconsistent.
-
Cerebral blood flow (CBF): Normobaric hyperoxemia induces mild vasoconstriction—likely protective by limiting O₂ delivery—but not clinically proven to cause ischemia.
-
Hyperbaric oxygenation (HBO₂): Preclinical and limited clinical trials suggest HBO₂ can reduce apoptosis, edema, and ICP while improving O₂ delivery post-ischemia; however, trial data (e.g., stroke) remain inconclusive.
-
Clinical nuance: Harm/benefit of oxygen depends on timing, PaCO₂, pH, autoregulation, and etiology of ABI—not a simple threshold effect.
Why This Matters: Blanket avoidance of hyperoxemia in ABI may be premature. Instead, context-specific O₂ titration—considering timing, etiology, and physiology—appears more rational than rigid PaO₂ thresholds.
Conclusion: Hyperoxemia should not be universally labeled harmful in ABI. While excess O₂ can cause oxidative stress, it may also provide therapeutic benefits (e.g., HBO₂). The effect is highly context-dependent, demanding individualized strategies and further prospective trials.
Take-Home for Clinicians:
-
Avoid simplistic PaO₂ cutoffs—focus on clinical context and metabolic state.
-
Consider HBO₂ selectively in ABI with ischemic or reperfusion components.
-
Balance O₂ delivery against risk of pulmonary and systemic O₂ toxicity.
Discussion Question: Should future ABI protocols replace static PaO₂ thresholds with multimodal monitoring (PaO₂ + cerebral blood flow + ROS markers) to guide oxygen therapy?
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
